Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells.

Aleksic T, Chitnis MM, Perestenko OV, Gao S, Thomas PH, Turner GD, Protheroe AS, Howarth M, Macaulay VM.

Cancer Res. 2010 Aug 15;70(16):6412-9. doi: 10.1158/0008-5472.CAN-10-0052.

2.

Unregulated ARF6 activation in epithelial cysts generates hyperactive signaling endosomes and disrupts morphogenesis.

Tushir JS, Clancy J, Warren A, Wrobel C, Brugge JS, D'Souza-Schorey C.

Mol Biol Cell. 2010 Jul 1;21(13):2355-66. doi: 10.1091/mbc.E09-09-0824. Epub 2010 May 12.

3.

SUMOylation mediates the nuclear translocation and signaling of the IGF-1 receptor.

Sehat B, Tofigh A, Lin Y, Trocmé E, Liljedahl U, Lagergren J, Larsson O.

Sci Signal. 2010 Feb 9;3(108):ra10. doi: 10.1126/scisignal.2000628.

4.

Potential role of tissue microarrays for the study of biomarker expression in benign breast disease and normal breast tissue.

Collins LC, Wang Y, Connolly JL, Baer HJ, Hu R, Schnitt SJ, Colditz GA, Tamimi RM.

Appl Immunohistochem Mol Morphol. 2009 Oct;17(5):438-41. doi: 10.1097/PAI.0b013e3181993d86.

5.

Endocytosis and intracellular trafficking of ErbBs.

Sorkin A, Goh LK.

Exp Cell Res. 2009 Feb 15;315(4):683-96. Review.

PMID:
19278030
6.

Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions.

Kleinberg DL, Wood TL, Furth PA, Lee AV.

Endocr Rev. 2009 Feb;30(1):51-74. doi: 10.1210/er.2008-0022. Epub 2008 Dec 15. Review. Erratum in: Endocr Rev. 2012 Dec;33(6):1038.

PMID:
19075184
7.

IGF-1 receptor inhibitors in clinical trials--early lessons.

Weroha SJ, Haluska P.

J Mammary Gland Biol Neoplasia. 2008 Dec;13(4):471-83. doi: 10.1007/s10911-008-9104-6. Epub 2008 Nov 21. Review.

8.

Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation.

Sigismund S, Argenzio E, Tosoni D, Cavallaro E, Polo S, Di Fiore PP.

Dev Cell. 2008 Aug;15(2):209-19. doi: 10.1016/j.devcel.2008.06.012.

9.

Identification of c-Cbl as a new ligase for insulin-like growth factor-I receptor with distinct roles from Mdm2 in receptor ubiquitination and endocytosis.

Sehat B, Andersson S, Girnita L, Larsson O.

Cancer Res. 2008 Jul 15;68(14):5669-77. doi: 10.1158/0008-5472.CAN-07-6364.

10.

The relative distribution of membranous and cytoplasmic met is a prognostic indicator in stage I and II colon cancer.

Ginty F, Adak S, Can A, Gerdes M, Larsen M, Cline H, Filkins R, Pang Z, Li Q, Montalto MC.

Clin Cancer Res. 2008 Jun 15;14(12):3814-22. doi: 10.1158/1078-0432.CCR-08-0180.

11.

IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor.

Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, Ludwig DL.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5549s-5555s. Review.

12.

Insulin-like growth factor type-I receptor internalization and recycling mediate the sustained phosphorylation of Akt.

Romanelli RJ, LeBeau AP, Fulmer CG, Lazzarino DA, Hochberg A, Wood TL.

J Biol Chem. 2007 Aug 3;282(31):22513-24. Epub 2007 Jun 1.

13.

Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation.

Jones RA, Campbell CI, Gunther EJ, Chodosh LA, Petrik JJ, Khokha R, Moorehead RA.

Oncogene. 2007 Mar 8;26(11):1636-44. Epub 2006 Sep 4.

PMID:
16953219
14.

The influence of family history on breast cancer risk in women with biopsy-confirmed benign breast disease: results from the Nurses' Health Study.

Collins LC, Baer HJ, Tamimi RM, Connolly JL, Colditz GA, Schnitt SJ.

Cancer. 2006 Sep 15;107(6):1240-7.

15.

IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC).

Rinaldi S, Peeters PH, Berrino F, Dossus L, Biessy C, Olsen A, Tjonneland A, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Téhard B, Nagel G, Linseisen J, Boeing H, Lahmann PH, Trichopoulou A, Trichopoulos D, Koliva M, Palli D, Panico S, Tumino R, Sacerdote C, van Gils CH, van Noord P, Grobbee DE, Bueno-de-Mesquita HB, Gonzalez CA, Agudo A, Chirlaque MD, Barricarte A, Larrañaga N, Quiros JR, Bingham S, Khaw KT, Key T, Allen NE, Lukanova A, Slimani N, Saracci R, Riboli E, Kaaks R.

Endocr Relat Cancer. 2006 Jun;13(2):593-605.

16.

Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II.

Schernhammer ES, Holly JM, Hunter DJ, Pollak MN, Hankinson SE.

Endocr Relat Cancer. 2006 Jun;13(2):583-92.

17.

Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on.

Renehan AG, Harvie M, Howell A.

Endocr Relat Cancer. 2006 Jun;13(2):273-8. Review.

18.
19.

Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor.

Carboni JM, Lee AV, Hadsell DL, Rowley BR, Lee FY, Bol DK, Camuso AE, Gottardis M, Greer AF, Ho CP, Hurlburt W, Li A, Saulnier M, Velaparthi U, Wang C, Wen ML, Westhouse RA, Wittman M, Zimmermann K, Rupnow BA, Wong TW.

Cancer Res. 2005 May 1;65(9):3781-7.

20.

The Nurses' Health Study: lifestyle and health among women.

Colditz GA, Hankinson SE.

Nat Rev Cancer. 2005 May;5(5):388-96. Review.

PMID:
15864280
Items per page

Supplemental Content

Write to the Help Desk